巨子生物控股有限公司（股票代码：2367）于2026年1月14日披露翌日披露报表，显示公司当日以每股35.1港元至35.8港元的价格，在香港联交所回购40万股普通股，合计支付约1415万港元。公司确认上述回购行为遵照相关上市规则及法例进行。
根据公告，截至上述回购完成后，公司已发行股本总数仍为约10.70904亿股，库藏股结存数目为0股。公司表示，此次股份购回依据2025年6月13日获股东大会通过的回购授权开展。该授权允许最高回购总数为1.070904亿股，而公司目前已累计回购约840万股，占回购授权通过当日已发行股份约0.7844%。
公司在公告中进一步确认，所有回购事宜均遵守香港联交所《主板上市规则》及相关规定。上述公告由执行董事兼联席公司秘书严鈺博签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.